Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

A Review of Scientific Literature of Interest to Office-Based Anesthesiology Practitioners.

Saxen MA, Urman RD, Homsi JT.

Anesth Prog. 2019 Summer;66(2):111-114. doi: 10.2344/anpr-66-02-11. No abstract available.

PMID:
31184946
2.

A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma.

McQuade JL, Homsi J, Torres-Cabala CA, Bassett R, Popuri RM, James ML, Vence LM, Hwu WJ.

BMC Cancer. 2018 Dec 19;18(1):1274. doi: 10.1186/s12885-018-5193-9.

3.

LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration.

Deng M, Gui X, Kim J, Xie L, Chen W, Li Z, He L, Chen Y, Chen H, Luo W, Lu Z, Xie J, Churchill H, Xu Y, Zhou Z, Wu G, Yu C, John S, Hirayasu K, Nguyen N, Liu X, Huang F, Li L, Deng H, Tang H, Sadek AH, Zhang L, Huang T, Zou Y, Chen B, Zhu H, Arase H, Xia N, Jiang Y, Collins R, You MJ, Homsi J, Unni N, Lewis C, Chen GQ, Fu YX, Liao XC, An Z, Zheng J, Zhang N, Zhang CC.

Nature. 2018 Oct;562(7728):605-609. doi: 10.1038/s41586-018-0615-z. Epub 2018 Oct 17.

4.

"SIMBurns": A high-fidelity simulation program in emergency burn management developed through international collaboration.

D'Asta F, Homsi J, Sforzi I, Wilson D, de Luca M.

Burns. 2019 Feb;45(1):120-127. doi: 10.1016/j.burns.2018.08.030. Epub 2018 Sep 26.

PMID:
30268630
5.

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.

Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, Rabinowits G, Thai AA, Dunn LA, Hughes BGM, Khushalani NI, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker HM, Brana I, Gil-Martin M, Homsi J, Johnson ML, Moreno V, Niu J, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG.

N Engl J Med. 2018 Jul 26;379(4):341-351. doi: 10.1056/NEJMoa1805131. Epub 2018 Jun 4.

6.

Phase I/II Study of Hepatic Arterial Infusion of Nab-paclitaxel in Patients With Metastatic Melanoma to the Liver.

Vera-Aguilera J, Bedikian AY, Bassett RL, Hwu WJ, Kim KB, Qin Y, Cain S, Washington EW, Davies MA, Patel SM, Homsi J, Papadopoulos NE, Hwu P, Patel SP.

Am J Clin Oncol. 2018 Mar 5. doi: 10.1097/COC.0000000000000436. [Epub ahead of print]

PMID:
29509591
7.

Uncommon BRAF Mutations Associated with Durable Response to Immunotherapy in Patients with Metastatic Melanoma.

Swofford BP, Homsi J.

Case Rep Oncol Med. 2017;2017:8241624. doi: 10.1155/2017/8241624. Epub 2017 Oct 18.

8.

The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis.

Puri A, Homsi J.

Melanoma Res. 2017 Oct;27(5):519-523. doi: 10.1097/CMR.0000000000000387.

PMID:
28817445
9.

A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma.

Patel SP, Kim DW, Bassett RL, Cain S, Washington E, Hwu WJ, Kim KB, Papadopoulos NE, Homsi J, Hwu P, Bedikian AY.

Cancer Immunol Immunother. 2017 Oct;66(10):1359-1366. doi: 10.1007/s00262-017-2030-y. Epub 2017 Jun 13.

10.

A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.

Hersh EM, Del Vecchio M, Brown MP, Kefford R, Loquai C, Testori A, Bhatia S, Gutzmer R, Conry R, Haydon A, Robert C, Ernst S, Homsi J, Grob JJ, Kendra K, Agarwala SS, Li M, Clawson A, Brachmann C, Karnoub M, Elias I, Renschler MF, Hauschild A.

Ann Oncol. 2015 Nov;26(11):2267-74. doi: 10.1093/annonc/mdv324. Epub 2015 Sep 26.

11.

Introducing the advanced burn life support (ABLS) course in Italy.

D'Asta F, Homsi J, Clark P, Buffalo MC, Melandri D, Carboni A, Pinzauti E, Graziano A, Masellis A, Bussolin L, Messineo A.

Burns. 2014 May;40(3):475-9. doi: 10.1016/j.burns.2013.08.004. Epub 2013 Aug 29.

PMID:
23992873
12.

Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccination.

Vence LM, Wang C, Pappu H, Anson RE, Patel TA, Miller P, Bassett R, Lizee G, Overwijk WW, Komanduri K, Benjamin C, Alvarado G, Patel SP, Kim K, Papadopoulos NE, Bedikian AY, Homsi J, Hwu WJ, Boyd R, Radvanyi L, Hwu P.

J Immunother. 2013 May;36(4):276-86. doi: 10.1097/CJI.0b013e31829419f3.

13.

Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.

Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G, Glass M, Johnson VE, McMannis JD, Shpall E, Prieto V, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Patel S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Davies MA, Mansaray R, Fulbright OJ, Toth C, Ramachandran R, Wardell S, Gonzalez A, Hwu P.

Clin Cancer Res. 2012 Dec 15;18(24):6758-70. doi: 10.1158/1078-0432.CCR-12-1177. Epub 2012 Oct 2.

14.

BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma.

Kim J, Lazar AJ, Davies MA, Homsi J, Papadopoulos NE, Hwu WJ, Bedikian AY, Woodman SE, Patel SP, Hwu P, Kim KB.

J Cutan Pathol. 2012 Sep;39(9):821-5. doi: 10.1111/j.1600-0560.2012.01950.x. Epub 2012 Jul 19.

15.

Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy.

Noor R, Bedikian AY, Mahoney S, Bassett R Jr, Kim K, Papadopoulos N, Hwu WJ, Hwu P, Homsi J.

Support Care Cancer. 2012 Oct;20(10):2583-8. doi: 10.1007/s00520-011-1359-6. Epub 2012 Jan 25.

PMID:
22274951
16.

Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy.

Joseph RW, Peddareddigari VR, Liu P, Miller PW, Overwijk WW, Bekele NB, Ross MI, Lee JE, Gershenwald JE, Lucci A, Prieto VG, McMannis JD, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Hwu P, Radvanyi LG.

Clin Cancer Res. 2011 Jul 15;17(14):4882-91. doi: 10.1158/1078-0432.CCR-10-2769. Epub 2011 Jun 1.

17.

Pelvic computed tomography scans for surveillance in patients with primary melanoma in the head and neck.

Alvarado GC, Papadopoulos NE, Hwu WJ, Bedikian AY, Homsi J, Myers JN, Bronstein Y, Bassett RL, Hwu P, Kim KB.

Melanoma Res. 2011 Apr;21(2):127-30. doi: 10.1097/CMR.0b013e3283426821.

PMID:
21169870
18.

Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma.

Bedikian AY, Wei C, Detry M, Kim KB, Papadopoulos NE, Hwu WJ, Homsi J, Davies M, McIntyre S, Hwu P.

Am J Clin Oncol. 2011 Dec;34(6):603-10. doi: 10.1097/COC.0b013e3181f9456a.

PMID:
21150567
19.

Immunotherapy of melanoma: an update.

Homsi J, Grimm JC, Hwu P.

Surg Oncol Clin N Am. 2011 Jan;20(1):145-63. doi: 10.1016/j.soc.2010.09.004. Review.

PMID:
21111964
20.

Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival?

Bedikian AY, Johnson MM, Warneke CL, Papadopoulos NE, Kim KB, Hwu WJ, McIntyre S, Rohlfs M, Homsi J, Hwu P.

Melanoma Res. 2011 Feb;21(1):84-90. doi: 10.1097/CMR.0b013e328341445f. Review.

PMID:
21102360
21.

Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function.

Bedikian AY, Silverman JA, Papadopoulos NE, Kim KB, Hagey AE, Vardeleon A, Hwu WJ, Homsi J, Davies M, Hwu P.

J Clin Pharmacol. 2011 Aug;51(8):1205-12. doi: 10.1177/0091270010381499. Epub 2010 Oct 26.

PMID:
20978276
22.

Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma.

Homsi J, Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Mahoney SL, Hwu P.

Melanoma Res. 2010 Dec;20(6):507-10. doi: 10.1097/CMR.0b013e3283403ce9.

PMID:
20881508
23.

Symptom severity and distress in advanced cancer.

Kirkova J, Walsh D, Rybicki L, Davis MP, Aktas A, Tao Jin, Homsi J.

Palliat Med. 2010 Apr;24(3):330-9. doi: 10.1177/0269216309356380. Epub 2009 Dec 16.

PMID:
20015920
24.

A comparative study of 2 sustained-release morphine preparations for pain in advanced cancer.

Homsi J, Walsh D, Lasheen W, Nelson KA, Rybicki LA, Bast J, LeGrand SB.

Am J Hosp Palliat Care. 2010 Mar;27(2):99-105. doi: 10.1177/1049909109345146. Epub 2009 Sep 23.

PMID:
19776372
25.

Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients.

Homsi J, Bedikian AY, Kim KB, Papadopoulos NE, Hwu WJ, Mahoney SL, Hwu P.

Melanoma Res. 2009 Aug;19(4):238-42. doi: 10.1097/CMR.0b013e32832a1e2f.

PMID:
19521262
26.

Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma.

Papadopoulos NE, Bedikian A, Ring S, Kim KB, Hwu WJ, Gerber DL, Homsi J, Hwu P.

Am J Clin Oncol. 2009 Oct;32(5):509-14. doi: 10.1097/COC.0b013e3181942a1f.

PMID:
19506454
27.

A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma.

Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Homsi J, Glass MR, Cain S, Rudewicz P, Vernillet L, Hwu P.

Cancer Invest. 2009 Aug;27(7):756-63. doi: 10.1080/07357900802709159.

PMID:
19440934
28.

Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.

Homsi J, Cubitt CL, Zhang S, Munster PN, Yu H, Sullivan DM, Jove R, Messina JL, Daud AI.

Melanoma Res. 2009 Jun;19(3):167-75. doi: 10.1097/CMR.0b013e328304974c.

PMID:
19434004
29.

Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies.

Homsi J, Simon GR, Garrett CR, Springett G, De Conti R, Chiappori AA, Munster PN, Burton MK, Stromatt S, Allievi C, Angiuli P, Eisenfeld A, Sullivan DM, Daud AI.

Clin Cancer Res. 2007 Oct 1;13(19):5855-61.

30.

Symptoms and survival in patients with advanced disease.

Homsi J, Luong D.

J Palliat Med. 2007 Aug;10(4):904-9. Review.

PMID:
17803412
31.

Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors.

Homsi J, Daud AI.

Cancer Control. 2007 Jul;14(3):285-94. Review.

PMID:
17615535
32.

Melanoma of the anal canal: a case series.

Homsi J, Garrett C.

Dis Colon Rectum. 2007 Jul;50(7):1004-10.

PMID:
17468984
33.

The Src signaling pathway: a potential target in melanoma and other malignancies.

Homsi J, Cubitt C, Daud A.

Expert Opin Ther Targets. 2007 Jan;11(1):91-100. Review.

PMID:
17150037
34.

Hepatic arterial infusion of chemotherapy for hepatic metastases from colorectal cancer.

Homsi J, Garrett CR.

Cancer Control. 2006 Jan;13(1):42-7.

PMID:
16508625
35.

Symptom evaluation in palliative medicine: patient report vs systematic assessment.

Homsi J, Walsh D, Rivera N, Rybicki LA, Nelson KA, Legrand SB, Davis M, Naughton M, Gvozdjan D, Pham H.

Support Care Cancer. 2006 May;14(5):444-53. Epub 2006 Jan 10.

PMID:
16402231
36.

Cutaneous melanoma: prognostic factors.

Homsi J, Kashani-Sabet M, Messina JL, Daud A.

Cancer Control. 2005 Oct;12(4):223-9. Review.

PMID:
16258493
37.

A phase II study of hydrocodone for cough in advanced cancer.

Homsi J, Walsh D, Nelson KA, Sarhill N, Rybicki L, Legrand SB, Davis MP.

Am J Hosp Palliat Care. 2002 Jan-Feb;19(1):49-56.

PMID:
12171425
38.

Palliative medicine in a United States cancer center: a prospective study.

Cowan JD, Walsh D, Homsi J.

Am J Hosp Palliat Care. 2002 Jul-Aug;19(4):240-50.

PMID:
12141788
39.

The impact of a palliative medicine consultation service in medical oncology.

Homsi J, Walsh D, Nelson KA, LeGrand SB, Davis M, Khawam E, Nouneh C.

Support Care Cancer. 2002 May;10(4):337-42. Epub 2002 Feb 15.

PMID:
12029434
40.

Symptom assessment in cancer patients.

Naughton M, Homsi J.

Curr Oncol Rep. 2002 May;4(3):256-63. Review.

PMID:
11937017
41.

Hydrocodone for cough in advanced cancer.

Homsi J, Walsh D, Nelson KA, LeGrand SB, Davis M.

Am J Hosp Palliat Care. 2000 Sep-Oct;17(5):342-6.

PMID:
11886059
42.

Methylphenidate for depression in hospice practice: a case series.

Homsi J, Walsh D, Nelson KA, LeGrand S, Davis M.

Am J Hosp Palliat Care. 2000 Nov-Dec;17(6):393-8.

PMID:
11886041
43.

Important drugs for cough in advanced cancer.

Homsi J, Walsh D, Nelson KA.

Support Care Cancer. 2001 Nov;9(8):565-74. Review.

PMID:
11762966
44.

A phase II study of methylphenidate for depression in advanced cancer.

Homsi J, Nelson KA, Sarhill N, Rybicki L, LeGrand SB, Davis MP, Walsh D.

Am J Hosp Palliat Care. 2001 Nov-Dec;18(6):403-7.

PMID:
11712722
45.

The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine.

Davis MP, Homsi J.

Support Care Cancer. 2001 Sep;9(6):442-51. Review.

PMID:
11585271
46.

Methylphenidate for fatigue in advanced cancer: a prospective open-label pilot study.

Sarhill N, Walsh D, Nelson KA, Homsi J, LeGrand S, Davis MP.

Am J Hosp Palliat Care. 2001 May-Jun;18(3):187-92.

PMID:
11406895
47.

Infectious complications of advanced cancer.

Homsi J, Walsh D, Panta R, Lagman R, Nelson KA, Longworth DL.

Support Care Cancer. 2000 Nov;8(6):487-92.

PMID:
11094994
48.

Psychostimulants in supportive care.

Homsi J, Walsh D, Nelson KA.

Support Care Cancer. 2000 Sep;8(5):385-97. Review.

PMID:
10975688
49.

Bioelectrical impedance, cancer nutritional assessment, and ascites.

Sarhill N, Walsh D, Nelson K, Homsi J, Komurcu S.

Support Care Cancer. 2000 Jul;8(4):341-3.

PMID:
10923777
50.

Common complications of advanced cancer.

Nelson KA, Walsh D, Abdullah O, McDonnell F, Homsi J, Komurcu S, LeGrand SB, Zhukovsky DS.

Semin Oncol. 2000 Feb;27(1):34-44. Review.

PMID:
10697020

Supplemental Content

Support Center